Cristiana Griffante

发表

Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells.

E. Perdona', R. Arban, Cristiana Griffante, 2012, European journal of pharmacology.

Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist

Alan A. Wilson, S. Houle, M. Laruelle, 2010, Biological Psychiatry.

1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor Antagonists

J. Hagan, A. Schwarz, A. Capelli, 2007 .

Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist

A. Green, Bryony A Dickinson, O. Curcuruto, 2005, British journal of pharmacology.

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.

H. Carlisle, J. Bright, K. Zobel, 2020, Journal of Medicinal Chemistry.

Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.

Michael K. Trower, R. Carletti, S. Melotto, 2013, Bioorganic & medicinal chemistry.

Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors

K. Thor, M. Corsi, D. Ricca, 2019, Neuroscience Letters.

Affinity, potency, efficacy, and selectivity of neurokinin A analogs at human recombinant NK2 and NK1 receptors

K. Thor, E. Burgard, M. Corsi, 2018, PloS one.

Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.

S. Melotto, M. Corsi, D. Montanari, 2011, Journal of medicinal chemistry.

[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain

R. Carletti, M. Corsi, Cristiana Griffante, 2006, British journal of pharmacology.

Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.

S. Melotto, M. Corsi, D. Montanari, 2009, Journal of medicinal chemistry.

Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK(1) receptor antagonists.

A. Capelli, S. Melotto, M. Corsi, 2010, Bioorganic & medicinal chemistry letters.

NMDA-induced ERK signalling is mediated by NR2B subunit in rat cortical neurons and switches from positive to negative depending on stage of development

A. Sava, E. Bettini, C. Carignani, 2012, Neuropharmacology.

Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse

M. Corsi, M. Marchi, L. Bettelini, 2003, Neuroscience Letters.

Dimerization Between Vasopressin V1b and Corticotropin Releasing Hormone Type 1 Receptors

G. Aguilera, S. Young, Cristiana Griffante, 2007, Cellular and Molecular Neurobiology.

Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist

John D. Beaver, Mark Slifstein, Marc Laruelle, 2010, Biological Psychiatry.

Occupancy of Brain Dopamine D3 Receptors and Drug Craving: A Translational Approach

E. Rabiner, E. Pich, J. Beaver, 2013, Neuropsychopharmacology.

Identification and Characterization of Novel NMDA Receptor Antagonists Selective for NR2A- over NR2B-Containing Receptors

A. Capelli, A. Sava, E. Bettini, 2010, Journal of Pharmacology and Experimental Therapeutics.

Identification and Characterization of Novel NMDA Receptor Antagonists Selective for NR 2 A-over NR 2 B-Containing Receptors

A. Capelli, A. Sava, E. Bettini, 2010 .

1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.

A. Capelli, G. Tedesco, F. Blaney, 2010, Journal of medicinal chemistry.

Brain-Penetrant Cyanoindane and Cyanotetralin Inhibitors of G2019S-LRRK2 Kinase Activity.

A. Sava, Cristiana Griffante, A. W. Garofalo, 2023, Bioorganic & medicinal chemistry letters.